Evidence map›Paper›PMID 32272660›Full record

ArticleBiology2020

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro.

Rafia S Al-Lamki, Nicholas J Hudson, John R Bradley, Anne Y Warren, Tim Eisen, Sarah J Welsh, Antony C P Riddick, Fiach C O'Mahony, Arran Turnbull, Thomas Powles and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Rafia S Al-LamkiDepartment of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Nicholas J HudsonSchool of Agriculture and Food Sciences, University of Queensland, Gatton, QLD 4343, Australia.
John R BradleyDepartment of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Anne Y WarrenCambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.ORCID 0000-0002-1170-7867
Tim EisenCambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Sarah J WelshCambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.ORCID 0000-0001-5690-2677
Antony C P RiddickCambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Fiach C O'MahonyScottish Collaboration on Translational Research into Renal Cell Cancer (SCOTRRCC).
Arran TurnbullScottish Collaboration on Translational Research into Renal Cell Cancer (SCOTRRCC).
Thomas PowlesBart's Cancer Institute, Charterhouse Square, London EC1M 6BE, UK.
Scotrrcc CollaborativeScottish Collaboration on Translational Research into Renal Cell Cancer (SCOTRRCC).
Antonio ReverterCSIRO Agriculture and Food, Queensland Bioscience Precinct, St. Lucia, QLD 4067, Australia.
David J HarrisonScottish Collaboration on Translational Research into Renal Cell Cancer (SCOTRRCC).
Grant D StewartCambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.ORCID 0000-0003-3188-9140
University of Cambridge · GBCambridge University Hospitals NHS Foundation Trust · GBCommonwealth Scientific and Industrial Research Organisation · AUThe University of Queensland · AUUniversity of St Andrews · GB

Funding

Medical Research Council MR/T024097/1
6 · The paper itself

Abstract

Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we take steps towards validating a computational prediction based on differential transcriptome network analysis that phosphorylated adapter RNA export protein (PHAX) is associated with sunitinib drug treatment. The regulatory impact factor differential network algorithm run on patient tissue samples suggests PHAX is likely an important regulator through changes in genome-wide network connectivity. Immunofluorescence staining of patient tumours showed strong localisation of PHAX to the microvasculature consistent with the anti-angiogenic effect of sunitinib. In normal kidney tissue, PHAX protein abundance was low but increased with tumour grade (G1 vs. G3/4;

Indexed as

kidney cancerorgan culturePHAXrenal cancersunitinib

Identifiers

PMID32272660
PMCPMC7236799
OpenAlexW3015772178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.